Zacks
0
All posts from Zacks
Zacks in Our Research. Your Success.,

The Zacks Analyst Blog Highlights: Alcobra, Editas Medicine, Syndax Pharmaceuticals, Seres Therapeutics and Neos Therapeutics

For Immediate Release

Chicago, IL – May 16, 2016 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Alcobra Ltd. (ADHD), Editas Medicine Inc. (EDIT), Syndax Pharmaceuticals, Inc. (SNDX), Seres Therapeutics, Inc. (MCRB) and Neos Therapeutics, Inc. (NEOS).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Friday’s Analyst Blog:

Drug Stock Earnings to Watch for Monday

The Q1 earnings season is almost wrapping up with 90.2% (as of May 11) of the S&P 500 members having already reported results. Now how does the picture look like? While growth remained nonexistent, the results were not that bad with a number of companies coming out with positive surprises for both earnings as well as revenues.

However, 2016 earnings growth expectations have turned negative similar to what was seen last year. www.zacks.com/commentary/80703/will-hopes-of-earnings-growth..." target="_blank"> Will Hopes of Earnings Growth Materialize ? As most of the remaining companies report Q1 results over the next coming days, things will become clearer.

With several pharma and major biotech companies having released their earnings results, Medical is one of the few sectors witnessing earnings and revenue growth in Q1. Our Q1 scorecard shows that 94.3% of the Medical sector has reported results with earnings growth of 7.8% and revenue growth of 9.8%. The blended beat stands at 64% (the percentage of companies that have beaten both EPS as well as revenue estimates).

Notably, the Medical sector is anticipated to be one of the seven sectors to record earnings growth (7.6%) in Q1, as per our Earnings Trends report.

Among drug stocks lined up to report on May 16, let’s take a sneak peek at five companies.

Headquartered in Tel Aviv, Israel, Alcobra Ltd. (ADHD) is an emerging pharmaceutical company focused on the development of treatments for cognitive disorders including attention deficit hyperactivity disorder and fragile X syndrome. Alcobra has been seen to consistently beat expectations with an average positive surprise of 21.53%. This Zacks Rank #3 (Hold) stock has an Earnings ESP of 0.00% for the first quarter thereby making it difficult to predict a beat.

Editas Medicine Inc. (EDIT) is one of the leading genome editing company developing a proprietary genome editing platform based on CRISPR/Cas9 technology. The company is looking to treat patients with genetically defined diseases by correcting their disease causing genes. This Cambridge, MA-based company, which started trading from Feb 2016, has a Zacks Rank #3 which when combined with an ESP of 0.00% makes a surprise prediction difficult.

Based in Waltham, MA, Syndax Pharmaceuticals, Inc. (SNDX) is a development-stage biopharmaceutical company focused on the development of entinostat as a combination therapy in multiple cancer indications. Syndax started trading from March this year. The company’s Zacks Rank #3 with an ESP of 0.00% once again makes a surprise prediction difficult this quarter.

One of the leading microbiome therapeutics platform companies, Seres Therapeutics, Inc.( MCRB) is a development stage company focused on the development of a novel class of biological drugs designed to treat disease by restoring the function of a dysbiotic microbiome. This Cambridge, MA-based company, which started trading from Jun 2015, has delivered disappointing performances in both its reported quarters with the company missing estimates with a negative surprise of 19.11%. The company’s Zacks Rank #3 with an ESP of 0.00% makes a surprise prediction difficult this quarter.

Grand Prairie, TX-based Neos Therapeutics, Inc.’s (NEOS) Zacks Rank #2 (Buy) increases the predictive power of the ESP. However, the company’s 0.00% ESP makes a surprise prediction difficult yet again. Neos is a pharmaceutical company focused on the development, manufacturing and commercialization of products utilizing its proprietary modified-release drug delivery technology platforms. The company, which started trading from Jul 2015, reported a positive surprise of 22.97% last quarter.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today. Find out What is happening in the stock market today on zacks.com.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
ALCOBRA LTD (ADHD): Free Stock Analysis Report
 
EDITAS MEDICINE (EDIT): Free Stock Analysis Report
 
SYNDAX PHARMA (SNDX): Free Stock Analysis Report
 
SERES THERAPEUT (MCRB): Free Stock Analysis Report
 
NEOS THERAPTCS (NEOS): Free Stock Analysis Report
 
To read this article on Zacks.com click here.